Beyond hs-CRP: Could suPAR Reveal Hidden Heart Risk in Type 2 Diabetes?

People with type 2 diabetes can face substantial cardiovascular risk even when clinicians address familiar risk factors such as LDL cholesterol, blood pressure, smoking, and blood glucose. Could another blood marker help reveal some of the risk that remains? Emerging research on the suPAR biomarker in diabetes suggests it may provide information about chronic immune activation and inflammation that high-sensitivity C-reactive protein, or hs-CRP, does not fully capture. However, suPAR remains an emerging risk marker rather than a routine diabetes screening test.

Table of Contents

• What suPAR measures compared with hs-CRP
• What recent type 2 diabetes research found
• How suPAR could affect cardiovascular risk assessment
• Why routine suPAR screening is premature
• Conclusion
• Frequently asked questions

suPAR vs. hs-CRP: Two Different Views of Inflammation

Inflammation plays an important role in cardiovascular disease, but no single blood test captures every part of that process. hs-CRP is a familiar inflammatory marker that rises in response to signals associated with inflammation. Clinicians and researchers have therefore used it to help assess inflammatory cardiovascular risk in selected settings.

suPAR, short for soluble urokinase plasminogen activator receptor, offers a different window into inflammation. The protein is related to uPAR, which is found on immune cells. When uPAR is released into circulation in soluble form, blood suPAR levels can reflect ongoing immune system activity.

Importantly, suPAR appears to provide information that is not identical to hs-CRP. Research has linked higher suPAR concentrations with cardiovascular disease, kidney dysfunction, and mortality. A 2024 review, for example, described suPAR as a potential indicator of inflammatory activation and disease burden across several cardiovascular conditions. Read the review on PubMed.

That distinction may matter in diabetes. Rather than simply asking whether inflammation is present, research on suPAR in diabetes raises a more specific question: Could suPAR identify persistent immune-related cardiovascular risk that traditional inflammatory markers miss?

New Evidence Links suPAR With Cardiovascular Risk in Type 2 Diabetes

A 2026 study published in Diabetes Care provides important evidence. Researchers analyzed 4,324 participants from the Emory Cardiovascular Biobank, including 31.8% with type 2 diabetes. Participants were followed for a median of 6.9 years. View the study on PubMed.

Notably, people with type 2 diabetes had higher median suPAR levels than those without diabetes. Type 2 diabetes was also associated with a 38% higher adjusted risk of cardiovascular death before suPAR was added to the statistical model. After researchers adjusted for suPAR, however, that association weakened and was no longer statistically significant. Adjustment for hs-CRP did not produce the same result.

Moreover, the investigators estimated that suPAR, but not hs-CRP, mediated more than half of the association between type 2 diabetes and the adverse outcomes studied. Similar patterns appeared for cardiovascular death combined with myocardial infarction and for all-cause mortality.

These findings do not prove that suPAR causes cardiovascular events. Because the evidence is observational, other biological and clinical factors may contribute to the associations. Still, the results suggest that chronic immune dysregulation measured through suPAR could represent an important component of residual cardiovascular risk in type 2 diabetes.

Could suPAR Improve Cardiovascular Risk Assessment in Diabetes?

The potential value of suPAR becomes clearer when viewed alongside conventional risk assessment. Clinicians already consider factors such as age, blood pressure, cholesterol, kidney function, smoking, glycemic status, and established cardiovascular disease when evaluating a person with diabetes.

Yet cardiovascular events can still occur despite aggressive management of these factors. Therefore, researchers continue searching for biomarkers that can refine risk estimates and uncover biological pathways not represented by standard measurements.

The potential link between suPAR and cardiovascular risk in diabetes is particularly interesting because previous studies have found associations independent of CRP and conventional cardiovascular risk factors. Earlier population research showed that elevated suPAR predicted cardiovascular disease, type 2 diabetes, and mortality after adjustment for several established risk factors, including CRP. See the earlier population study.

More recent evidence strengthens that picture. A large 2026 UK Biobank analysis found that higher proteomics-based suPAR levels predicted major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality independently of clinical risk factors and hs-CRP. Adding suPAR also produced a modest improvement in cardiovascular risk discrimination.

Meanwhile, suPAR has attracted interest beyond coronary artery disease. In a 2026 analysis of patients with type 2 diabetes and worsening heart failure, higher baseline suPAR showed a graded association with poorer cardiovascular outcomes even after adjustment for factors including kidney function and NT-proBNP.

Together, these findings make suPAR scientifically compelling. However, better prediction in research does not automatically mean a biomarker improves patient care.

Why Routine suPAR Screening Is Not Ready for Diabetes Care

For a new biomarker to become clinically useful, researchers must show more than an association with future events. Ideally, testing should meaningfully change risk classification, guide treatment decisions, and ultimately improve outcomes.

At present, those steps have not been established for routine suPAR testing in type 2 diabetes. The American Diabetes Association’s 2026 cardiovascular risk-management standards address extensive evidence-based strategies for reducing cardiovascular risk, while suPAR has not become an established routine screening marker for diabetes care.

In addition, clinicians would need practical guidance on how to interpret results. A high suPAR concentration can occur in several diseases and inflammatory states. Therefore, it is not a diabetes-specific or cardiovascular-specific signal.

Researchers also need to determine whether lowering suPAR itself changes cardiovascular outcomes. That distinction is crucial because a biomarker can predict disease without being an effective treatment target. For example, a recent study involving sotagliflozin found that the drug’s cardiovascular benefits in patients with diabetes and worsening heart failure did not appear to result from reducing suPAR levels.

For now, clinicians should continue prioritizing proven cardiovascular risk-reduction strategies. These include appropriate lipid and blood pressure management, smoking cessation, healthy lifestyle measures, and evidence-based glucose-lowering therapies with cardiovascular benefits when indicated. Anyone concerned about personal cardiovascular risk should discuss individualized testing and treatment options with a qualified healthcare professional.

Conclusion

Emerging research on the suPAR biomarker in type 2 diabetes offers a potentially valuable look at cardiovascular risk beyond hs-CRP. Recent evidence suggests that elevated suPAR may reflect chronic inflammation and immune dysregulation associated with adverse outcomes in people with type 2 diabetes and coronary disease.

However, suPAR should not yet be viewed as a replacement for hs-CRP or conventional cardiovascular risk assessment. Instead, the two biomarkers may capture different aspects of inflammatory biology. Larger prospective studies and clinical trials are needed to determine whether measuring suPAR leads to treatment changes that improve outcomes.

For diabetes care, that is the key question. Predicting hidden risk is useful, but acting on that information in a way that protects patients is what ultimately matters.

Frequently Asked Questions

What is suPAR?

suPAR stands for soluble urokinase plasminogen activator receptor. It is a circulating protein associated with immune activation and chronic inflammation. Higher levels have been linked with cardiovascular, kidney, and other diseases.

How is suPAR different from hs-CRP?

Both are inflammatory biomarkers, but they reflect different biological processes. hs-CRP is an acute-phase inflammatory protein, while suPAR is more closely associated with immune activation and may reflect persistent systemic inflammation.

Does high suPAR mean someone will have a heart attack?

No. An elevated suPAR result does not predict with certainty that an individual will experience a heart attack. Research shows associations with higher cardiovascular risk, but suPAR must be interpreted alongside other health information.

Should people with type 2 diabetes get a suPAR test?

Routine suPAR screening is not currently an established part of standard diabetes cardiovascular risk assessment. More research is needed to determine whether testing improves clinical decisions and patient outcomes.

Could suPAR replace hs-CRP for cardiovascular risk assessment?

Current evidence does not support replacing hs-CRP with suPAR. Instead, research suggests the biomarkers may capture different aspects of inflammation. Future studies may clarify whether using them together improves cardiovascular risk assessment.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.